CTOs on the Move


 
Freyr is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.freyrinc.com
  • 103 Carnegie Ctr Ste 300
    Princeton, NJ USA 08540
  • Phone: 908.345.5984

Executives

Name Title Contact Details

Similar Companies

Xontogeny

Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease.

Imago BioSciences

Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.

Meso Scale Discovery

Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SHYFT Analytics

SHYFT has been an integral part of the life sciences ecosystem for over 10 years and as the market undergoes a dramatic transformation to deliver more personalized and value-based medicine, the role of SHYFT has never been more important. We built the SHYFT Platform to help life science companies integrate clinical and commercial data and translate it into patient-centric intelligence and analytics for use across functional groups, shortening development cycles and commercialization activities while improving the probability of success. With a long history of success and deep client partnerships, we understand the market transformation and the actionable intelligence required for successful launch, growth and maintenance of new therapies. At SHYFT, we collaborate with our clients to ensure their success not only today, but in the future by providing flexible, agile solutions based on deep industry expertise. With an impressive customer retention rate, we`re committed to our client`s success and serve as a true partner in the transformation.

Jasper Therapeutics

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.